{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:54:15Z","timestamp":1787003655790,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K07807"],"award-info":[{"award-number":["23K07807"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K16314"],"award-info":[{"award-number":["20K16314"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23H04926"],"award-info":[{"award-number":["23H04926"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K02003"],"award-info":[{"award-number":["24K02003"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-37740-3","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T02:37:44Z","timestamp":1770259064000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Synergistic targeting of the ARID2\u2013MYC axis by pomalidomide and panobinostat overcomes intrinsic IMiD resistance in multiple myeloma"],"prefix":"10.1038","volume":"16","author":[{"given":"Junichi","family":"Yamamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Asatsuma-Okumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Iwai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Handa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"37740_CR1","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s12032-025-02807-0","volume":"42","author":"H Sutanto","year":"2025","unstructured":"Sutanto, H. et al. Genetic, epigenetic, and molecular determinants of multiple myeloma and precursor plasma cell disorders: A pathophysiological overview. Med. Oncol. 42, 234 (2025).","journal-title":"Med. Oncol."},{"key":"37740_CR2","doi-asserted-by":"publisher","first-page":"793","DOI":"10.3390\/cancers17050793","volume":"17","author":"E Ortega-Vida","year":"2025","unstructured":"Ortega-Vida, E. et al. Evolution of survival in patients with multiple myeloma over two decades: A real-world experience from a medium-level hospital. Cancers 17, 793 (2025).","journal-title":"Cancers"},{"key":"37740_CR3","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1126\/science.1177319","volume":"327","author":"T Ito","year":"2010","unstructured":"Ito, T. et al. Identification of a primary target of thalidomide teratogenicity. Science 327, 1345\u20131350 (2010).","journal-title":"Science"},{"key":"37740_CR4","doi-asserted-by":"publisher","first-page":"6234","DOI":"10.1039\/D2CS00116K","volume":"51","author":"J Yamamoto","year":"2022","unstructured":"Yamamoto, J., Ito, T., Yamaguchi, Y. & Handa, H. Discovery of CRBN as a target of thalidomide: A breakthrough for progress in the development of protein degraders. Chem. Soc. Rev. 51, 6234\u20136250 (2022).","journal-title":"Chem. Soc. Rev."},{"key":"37740_CR5","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1244851","volume":"343","author":"J Kr\u00f6nke","year":"2014","unstructured":"Kr\u00f6nke, J. et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 343, 301\u2013305 (2014).","journal-title":"Science"},{"key":"37740_CR6","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1126\/science.1244917","volume":"343","author":"G Lu","year":"2014","unstructured":"Lu, G. et al. The myeloma drug Lenalidomide promotes the Cereblon-dependent destruction of Ikaros proteins. Science 343, 305\u2013309 (2014).","journal-title":"Science"},{"key":"37740_CR7","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1038\/leu.2013.38","volume":"27","author":"DJ DeAngelo","year":"2013","unstructured":"DeAngelo, D. J. et al. Phase IA\/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. Leukemia 27, 1628\u20131636 (2013).","journal-title":"Leukemia"},{"key":"37740_CR8","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","volume":"15","author":"JF San-Miguel","year":"2014","unstructured":"San-Miguel, J. F. et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: A multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 15, 1195\u20131206 (2014).","journal-title":"Lancet Oncol."},{"key":"37740_CR9","doi-asserted-by":"publisher","first-page":"794","DOI":"10.3324\/haematol.2009.015495","volume":"95","author":"EM Ocio","year":"2009","unstructured":"Ocio, E. M. et al. In vitro and in vivo rationale for the triple combination of Panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica 95, 794\u2013803 (2009).","journal-title":"Haematologica"},{"key":"37740_CR10","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1182\/bloodadvances.2017007427","volume":"1","author":"A Chari","year":"2017","unstructured":"Chari, A. et al. A phase 2 study of Panobinostat with Lenalidomide and weekly dexamethasone in myeloma. Blood Adv. 1, 1575\u20131583 (2017).","journal-title":"Blood Adv."},{"key":"37740_CR11","doi-asserted-by":"publisher","first-page":"e312","DOI":"10.1038\/bcj.2015.38","volume":"5","author":"T Hideshima","year":"2015","unstructured":"Hideshima, T. et al. Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma. Blood Cancer J. 5, e312 (2015).","journal-title":"Blood Cancer J."},{"key":"37740_CR12","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.yexcr.2018.01.005","volume":"363","author":"S Tang","year":"2018","unstructured":"Tang, S. et al. Crucial role of HO-1\/IRF4-dependent apoptosis induced by panobinostat and lenalidomide in multiple myeloma. Exp. Cell Res. 363, 196\u2013207 (2018).","journal-title":"Exp. Cell Res."},{"key":"37740_CR13","doi-asserted-by":"publisher","first-page":"106398","DOI":"10.1016\/j.leukres.2020.106398","volume":"95","author":"GW Kim","year":"2020","unstructured":"Kim, G. W. et al. A452, HDAC6-selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in imids-resistant multiple myeloma. Leuk. Res. 95, 106398 (2020).","journal-title":"Leuk. Res."},{"key":"37740_CR14","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13046-021-01909-7","volume":"40","author":"M Hirano","year":"2021","unstructured":"Hirano, M. et al. Small-molecule HDAC and AKT inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma. J. Exp. Clin. Cancer Res. 40, 110 (2021).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"37740_CR15","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1038\/s41589-020-0645-3","volume":"16","author":"J Yamamoto","year":"2020","unstructured":"Yamamoto, J. et al. Arid2 is a pomalidomide-dependent CRL4CRBN substrate in multiple myeloma cells. Nat. Chem. Biol. 16, 1208\u20131217 (2020).","journal-title":"Nat. Chem. Biol."},{"key":"37740_CR16","doi-asserted-by":"publisher","first-page":"100110","DOI":"10.1016\/j.crphar.2022.100110","volume":"3","author":"D Duarte","year":"2022","unstructured":"Duarte, D. & Vale, N. Evaluation of synergism in drug combinations and reference models for future orientations in oncology. Curr. Res. Pharmacol. Drug Discov. 3, 100110 (2022).","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"key":"37740_CR17","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","volume":"13","author":"B Yadav","year":"2015","unstructured":"Yadav, B., Wennerberg, K., Aittokallio, T. & Tang, J. Searching for drug synergy in complex dose\u2013response landscapes using an interaction potency model. Comput. Struct. Biotechnol. J. 13, 504\u2013513 (2015).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"37740_CR18","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1097\/CAD.0000000000000389","volume":"27","author":"K Suzuki","year":"2016","unstructured":"Suzuki, K. et al. Antimyeloma activity of bromodomain inhibitors on the human myeloma cell line U266 by downregulation of MYCL. Anticancer Drugs 27, 756\u2013765 (2016).","journal-title":"Anticancer Drugs"},{"key":"37740_CR19","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1038\/leu.2014.70","volume":"28","author":"M Affer","year":"2014","unstructured":"Affer, M. et al. Promiscuous myc locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma. Leukemia 28, 1725\u20131735 (2014).","journal-title":"Leukemia"},{"key":"37740_CR20","doi-asserted-by":"publisher","first-page":"8567","DOI":"10.1073\/pnas.0503221102","volume":"14","author":"T Hideshima","year":"2005","unstructured":"Hideshima, T. et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc. Natl. Acad. Sci. USA 14, 8567\u20138572 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"37740_CR21","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1182\/blood-2013-01-481325","volume":"122","author":"PG Richardson","year":"2013","unstructured":"Richardson, P. G. et al. Panorama 2: Panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood 122, 2331\u20132337 (2013).","journal-title":"Blood"},{"key":"37740_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12943-023-01736-8","volume":"22","author":"A Andrades","year":"2023","unstructured":"Andrades, A. et al. SWI\/SNF complexes in hematological malignancies: Biological implications and therapeutic opportunities. Mol. Cancer 22, 39 (2023).","journal-title":"Mol. Cancer"},{"key":"37740_CR23","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","volume":"153","author":"J Lov\u00e9n","year":"2013","unstructured":"Lov\u00e9n, J. et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153, 320\u2013334 (2013).","journal-title":"Cell"},{"key":"37740_CR24","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1101\/gad.232710.113","volume":"27","author":"J Shi","year":"2013","unstructured":"Shi, J. et al. Role of SWI\/SNF in acute leukemia maintenance and enhancer-mediated myc regulation. Genes Dev. 27, 2648\u20132662 (2013).","journal-title":"Genes Dev."},{"key":"37740_CR25","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.ccell.2024.05.026","volume":"42","author":"A Bolomsky","year":"2024","unstructured":"Bolomsky, A. et al. IRF4 requires arid1a to establish plasma cell identity in multiple myeloma. Cancer Cell 42, 1185-1201.e14 (2024).","journal-title":"Cancer Cell"},{"key":"37740_CR26","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1158\/1078-0432.CCR-22-3668","volume":"29","author":"K Kurata","year":"2023","unstructured":"Kurata, K. et al. BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma. Clin. Cancer Res. 29, 1807\u20131821 (2023).","journal-title":"Clin. Cancer Res."},{"key":"37740_CR27","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1158\/1078-0432.CCR-24-3790","volume":"31","author":"CD DiNardo","year":"2025","unstructured":"DiNardo, C. D. et al. A phase I study of FHD-286, a dual BRG1\/BRM (SMARCA4\/SMARCA2) inhibitor, in patients with advanced myeloid malignancies. Clin. Cancer Res. 31, 2327\u20132338 (2025).","journal-title":"Clin. Cancer Res."},{"key":"37740_CR28","doi-asserted-by":"publisher","first-page":"106055","DOI":"10.1016\/j.phrs.2021.106055","volume":"176","author":"A Kabir","year":"2022","unstructured":"Kabir, A. & Muth, A. Polypharmacology: The science of multi-targeting molecules. Pharmacol. Res. 176, 106055 (2022).","journal-title":"Pharmacol. Res."},{"key":"37740_CR29","doi-asserted-by":"crossref","unstructured":"Yamamoto, J., Handa, H. & Yamaguchi, Y. Thalidomide \u2013 From a Banned Drug to Molecular Glues, PROTACs, and New Concepts in Drug Discovery. In Polypharmacology (ed. Peters, J.-U.) 367\u2013383 (Wiley, 2024).","DOI":"10.1002\/9781394182862.ch24"},{"key":"37740_CR30","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","volume":"20","author":"S Zheng","year":"2022","unstructured":"Zheng, S. et al. Synergy finder plus: Toward better interpretation and annotation of drug combination screening datasets. Genomics Proteomics Bioinform. 20, 587\u2013596 (2022).","journal-title":"Genomics Proteomics Bioinform."},{"key":"37740_CR31","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.1038\/s41598-020-61027-w","volume":"10","author":"S Tateno","year":"2020","unstructured":"Tateno, S. et al. Genome-wide screening reveals a role for subcellular localization of CRBN in the anti-myeloma activity of pomalidomide. Sci. Rep. 10, 4012 (2020).","journal-title":"Sci. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37740-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37740-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37740-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T12:36:27Z","timestamp":1771590987000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37740-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["37740"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-37740-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"19 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7375"}}